Lexaria Awards Contract To A CRO To Perform The Co's Human Pilot Study #3, Which Will Evaluate A Dual Action GLP-1 + GIP
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience Corp. has hired a contract research organization to perform a human pilot study evaluating a dual action GLP-1 + GIP. The study will compare injected tirzepatide (Zepbound® by Eli Lilly) to a DehydraTECH-processed tirzepatide in capsule form.
May 23, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexaria Bioscience Corp. has initiated a human pilot study to evaluate the effectiveness of its DehydraTECH-processed tirzepatide in an oral capsule form.
The initiation of the study could lead to significant advancements in drug delivery technology, potentially increasing the company's market value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Lexaria Bioscience Corp.'s warrants (LEXXW) may see increased activity due to the initiation of the human pilot study on DehydraTECH-processed tirzepatide.
The study's potential success could drive interest in the company's warrants, leading to increased trading activity.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Eli Lilly's Zepbound® tirzepatide will be compared to Lexaria's DehydraTECH-processed tirzepatide in a new human pilot study.
While the study involves Eli Lilly's product, the primary focus is on Lexaria's new formulation. The impact on Eli Lilly's stock is likely to be neutral in the short term.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60